These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 22635080)

  • 1. Sunitinib treatment for refractory malignant pheochromocytoma.
    Nemoto K; Miura T; Shioji G; Tsuboi N
    Neuro Endocrinol Lett; 2012; 33(3):260-4. PubMed ID: 22635080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma.
    Park KS; Lee JL; Ahn H; Koh JM; Park I; Choi JS; Kim YR; Park TS; Ahn JH; Lee DH; Kim TW; Lee JS
    Jpn J Clin Oncol; 2009 May; 39(5):327-31. PubMed ID: 19264767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib for refractory malignant pheochromocytoma: two case reports.
    Hata J; Haga N; Ishibashi K; Takahashi N; Ogawa S; Kataoka M; Akaihata H; Satoh Y; Koguchi T; Kojima Y
    Int Urol Nephrol; 2014 Jul; 46(7):1309-12. PubMed ID: 24510251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
    Denorme M; Yon L; Roux C; Gonzalez BJ; Baudin E; Anouar Y; Dubessy C
    Cancer Lett; 2014 Oct; 352(2):236-44. PubMed ID: 25016061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial.
    Kroiss M; Quinkler M; Johanssen S; van Erp NP; Lankheet N; Pöllinger A; Laubner K; Strasburger CJ; Hahner S; Müller HH; Allolio B; Fassnacht M
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3495-503. PubMed ID: 22837187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.
    Jimenez C; Cabanillas ME; Santarpia L; Jonasch E; Kyle KL; Lano EA; Matin SF; Nunez RF; Perrier ND; Phan A; Rich TA; Shah B; Williams MD; Waguespack SG
    J Clin Endocrinol Metab; 2009 Feb; 94(2):386-91. PubMed ID: 19017755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Malignant pheochromocytoma with remarkable response to CVD chemotherapy--a case report].
    Suzuki M; Mikata N; Imao S; Ishiwata S; Nagano T
    Gan To Kagaku Ryoho; 2000 Jun; 27(6):921-4. PubMed ID: 10897222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochromocytoma.
    Sun FK; He HC; Su TW; Zhou WL; Huang X; Dai J; Shen ZJ
    Chin Med J (Engl); 2012 Jun; 125(12):2231-4. PubMed ID: 22884159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
    JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor.
    Matsumoto K; Sawaki A; Mizuno N; Hara K; Hijioka S; Niwa Y; Tajika M; Kawai H; Kondo S; Yamao K
    Jpn J Clin Oncol; 2011 Jan; 41(1):57-62. PubMed ID: 20858619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.
    Joshua AM; Ezzat S; Asa SL; Evans A; Broom R; Freeman M; Knox JJ
    J Clin Endocrinol Metab; 2009 Jan; 94(1):5-9. PubMed ID: 19001511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
    Ayala-Ramirez M; Chougnet CN; Habra MA; Palmer JL; Leboulleux S; Cabanillas ME; Caramella C; Anderson P; Al Ghuzlan A; Waguespack SG; Deandreis D; Baudin E; Jimenez C
    J Clin Endocrinol Metab; 2012 Nov; 97(11):4040-50. PubMed ID: 22965939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors.
    Feldman DR; Turkula S; Ginsberg MS; Ishill N; Patil S; Carousso M; Bosl GJ; Motzer RJ
    Invest New Drugs; 2010 Aug; 28(4):523-8. PubMed ID: 19547919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
    Li XS; Wu X; Zhao PJ; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; Wang G; He ZS; Zhou LQ; Jin J
    Chin Med J (Engl); 2011 Sep; 124(18):2920-4. PubMed ID: 22040503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma.
    Ayllon J; Beuselinck B; Morel A; Barrascout E; Medioni J; Scotte F; Oudard S
    Cancer Invest; 2011 May; 29(4):282-5. PubMed ID: 21469976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapy of malignant pheochromocytoma. Invitation to participate in a randomized multicenter study].
    Mundschenk J; Kopf D; Lehnert H
    Dtsch Med Wochenschr; 1998 Jan; 123(1-2):32-3. PubMed ID: 9465855
    [No Abstract]   [Full Text] [Related]  

  • 18. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
    Paglino C; Imarisio I; Ganini C; Morbini P; Vercelli A; Bregant C; Porta C
    Future Oncol; 2012 Dec; 8(12):1605-12. PubMed ID: 23231522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
    Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ;
    Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteinuria in metastatic pheochromocytoma is associated with an increased risk of Acute Respiratory Distress Syndrome, spontaneously or after therapy with 131I-meta-iodobenzylguanidine (131I-MIBG).
    Porzig A; Matthay KK; Dubois S; Pampaloni M; Damon L; Hawkins R; Goldsby R; Hollinger F; Fitzgerald P
    Horm Metab Res; 2012 Jun; 44(7):539-42. PubMed ID: 22588707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.